Domestic pharma maker Mankind pharma announced their partnership with Innovent Biologics to exclusively license and sell sintilimab, an advanced PD-1 immunotherapy, in the Indian market.
This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region,” the company said in a statement.
🔹According to The national cancer registry programme cancer has become a major health concern in India, with its burden projected to reach 29.8 million DALYs by 2025.
🔹Sintilimab, marketed as TYVYT (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly. Its mechanism of blocking the PD-1/PD-L1 pathway reactivates T-cells, enhancing the body’s natural ability to target and eliminate cancer cells.
“The drug has demonstrated remarkable efficacy and favorable safety across multiple major cancer types with eight approved indications in China, including non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin’s lymphoma. TYVYT (sintilimab injection), is one of the top therapy choices in immunotherapy, has already benefited millions of cancer patients since its launch in 2018. This versatile immunotherapy holds the potential to make a significant impact for oncology patients in India,” the company said.
♦️”By bringing this innovative therapy to the Indian market, we are committed to improving patient outcomes and reinforcing our position as a leader in oncology. Mankind Pharma brings its extensive pharmaceutical expertise and expansive distribution network to this partnership, with a robust field force of 16,000+ personnel and over 13,000 stockists across India. This ecosystem will be crucial in ensuring widespread access to sintilimab across urban and rural markets. The partnership represents more than a commercial agreement – it’s a commitment to transforming oncological care in India, making innovative treatments available to a broader patient population,” said Atish Majumdar – Sr President – Sales & Marketing, Mankind Pharma Limited.
